Otsuka Pharma and UCB re-focus collaboration
Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have agreed to focus their collaboration on the therapeutic area of central nervous system (CNS) disorders and to discontinue their collaboration in immunology.
The companies will end their co-development and co-promotion agreement for certolizumab pegol (already marketed by UCB as Cimzia and generating first-half 2011 sales of 143 million euros; $182 million) in Japan followed by an agreed upon transition period. The decision to discontinue its collaboration in immunology is in line with Otsuka Pharmaceutical’s clear priorities to focus in the future on CNS and oncology in its pharmaceutical business. No financial implications of the re-focussing were revealed.
Japanese filing for certolizumab due this quarter
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze